You may have heard about Symtuza, a medicine approved by the FDA in 2018 to treat people with HIV who have not been treated yet. It may also be used to replace another medicine for treating HIV in ...
Treatment with Symtuza (darunavir 800 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg) results in and maintains high virologic suppression rates, according to study findings ...
Building on positive 48-week data, Janssen released 96-week data demonstrating high rates of virogolic suppression and tolerability among antiretroviral therapy-naïve adults with HIV-1. In July, the ...
With Gift Aid, your generous donation of £10 would be worth £12.50 at no extra cost to you. Yes, I want to Gift Aid any donations made to NAM now, in the future and in the past four years I am a UK ...
Johnson & Johnson has won FDA approval for a new once-a-day HIV drug, adding to its growing portfolio of treatment options for the condition. Now J&J must find a way to distinguish the drug in an ...
Janssen has won US approval for its once-daily HIV pill Symtuza (D/C/F/TAF), which it hopes will improve patient adherence and resistance to treatment. Symtuza (D/C/F/TAF) combines Janssen’s darunavir ...
Symtuza is a 4-drug combination of darunavir, an HIV-1 protease inhibitor; cobicistat, a CYP3A inhibitor; and emtricitabine and tenofovir alafenamide. The Food and Drug Administration (FDA) has ...
Please provide your email address to receive an email when new articles are posted on . Janssen announced that it has received FDA approval for Symtuza, a once-daily, single-tablet, darunavir-based ...
NHS England (NHSE) has agreed to provide funding for Janssen’s Symtuza, a once-daily darunavir-based single tablet regimen (STR), for the treatment of HIV in adults and adolescents. NHS England (NHSE) ...
Janssen has unveiled new late-stage data on Symtuza showing positive long-term efficacy and safety in antiretroviral treatment-naïve adults with HIV. Janssen has unveiled new late-stage data on ...
With Gift Aid, your generous donation of £10 would be worth £12.50 at no extra cost to you. Yes, I want to Gift Aid any donations made to NAM now, in the future and in the past four years I am a UK ...
Symtuza is a 4-drug combination of darunavir, an HIV-1 protease inhibitor; cobicistat, a CYP3A inhibitor; and emtricitabine and tenofovir alafenamide. The Food and Drug Administration (FDA) has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results